Hot topics in renal cell carcinoma and rare tumors

In this podcast we’ll hear from experts in GU cancer on some of the most exciting clinical trial data in kidney cancer as well as some of the latest developments in rare tumors presented at the 2023 ASCO Genitourinary Cancers congress. We will be joined by Thomas Powles, MBBS, MRCP, MD, Barts Cancer Institute, London, UK, Michael Atkins, MD, Lombardi Comprehensive Cancer Center, Washington DC, Talal El Zarif, MD, Dana-Farber Cancer Institute, Boston, MA, Lucia Nappi, MD, University of British Columbia, Vancouver, Canada, Robert A. Huddart, PhD, FRCR, MRCP, MBBS, The Royal Marsden Hospital and The Institute of Cancer Research, London, UK. We will hear about outcomes by IMDC risk in the COSMIC-313 trial assessing cabozantinib plus nivolumab and ipilimumab and treatment-free survival outcomes of the HCRN G16-260 trial of nivolumab plus ipilimumab in advanced renal cell carcinoma. We’ll also discuss a longitudinal evaluation of plasma miR371 to detect minimal residual disease and early relapse of germ cell tumors and talk on the safety and efficacy of immune checkpoint inhibitors in penile squamous cell carcinoma, as well as the comparative cost-effectiveness of alternative imaging and surveillance schedules for testicular seminoma from the TRISST trial.